Politics Trump to tap ex-Glaxo exec, U.S. general for coronavirus vaccine effort

00:42  14 may  2020
00:42  14 may  2020 Source:   reuters.com

Trump says he believes there will be a coronavirus vaccine 'by the end of the year'

  Trump says he believes there will be a coronavirus vaccine 'by the end of the year' President Donald Trump said on Sunday that he was confident that there will be a coronavirus vaccine by the end of the year. The comment came during a Fox News town hall at the Lincoln Memorial in Washington. Public health officials have said a vaccine could take a year to 18 months. © Provided by CNBC President Donald Trump speaks during a meeting with Louisiana Governor John Bel Edwards (D-LA) in the Oval Office of the White House in Washington, DC on April 29, 2020.

(Bloomberg) -- President Donald Trump plans to name Moncef Slaoui, the former head of GlaxoSmithKline Plc’ s vaccines division, and Gustave Perna, a four-star U . S . general , to lead a Manhattan Project-style effort to develop a vaccine for the novel coronavirus

President Donald Trump was contradicted by a health expert on his coronavirus task force over the timing for a potential vaccine during a briefing Monday.

WASHINGTON (Reuters) - President Donald Trump is expected to tap a former GlaxoSmithKline executive and a U.S. general to spearhead the government's effort at developing a coronavirus vaccine on an accelerated schedule, officially called "Operation Warp Speed," an administration official said on Wednesday.

Donald Trump wearing a suit and tie: FILE PHOTO: U.S. President Donald Trump holds press briefing on coronavirus response at the White House in Washington © Reuters/Kevin Lamarque FILE PHOTO: U.S. President Donald Trump holds press briefing on coronavirus response at the White House in Washington

The former head of Glaxo's vaccines division, Moncef Slaoui, will serve as chief adviser on the operation and U.S. General Gustav Perna will act as its chief operating officer. Trump previously said he would be the top boss on the effort to develop, test and produce on a shortened timeline a vaccine against the deadly coronavirus that has caused a global pandemic.

Coronavirus: EU allocates € 1 billion to research

 Coronavirus: EU allocates € 1 billion to research HEALTH-CORONAVIRUS-UNION-DONORS: Coronavirus: EU allocates € 1 billion to research © Reuters / POOL New CORONAVIRUS: EU ALLOCATES A BILLION EUROS FOR RESEARCH BRUSSELS (Reuters) - The European Union will allocate one billion euros to the global search for a vaccine and a treatment against the new coronavirus, announced on Monday the president of the Commission, Ursula von der Leyen, at a donors' conference.

A vaccine or treatment that gets the "fast track" designation is eligible for the agency' s "priority review" status, under which the. (Reuters) - Moderna Inc said on Tuesday the U . S . Food and Drug Administration granted "fast track" designation to its experimental coronavirus vaccine , a move that

U . S . President Donald Trump on Monday hailed coronavirus testing efforts as the best in the world, but abruptly ended his Rose Garden news conference Fauci also contradicted Trump ’ s claims of last week that the virus would die out of its own accord — without a vaccine — and said the true U . S

The White House has set a target of having 300 million vaccine doses by the end of 2020. No such vaccine for this pathogen has been approved though a number are under development, and producing and distributing an effective vaccine are seen as key steps to jumpstarting the U.S. economy.

When Slaoui retired nearly three years ago from the drugmaker, its vaccines unit had 15 products in development, including one for Ebola, another killer virus. Slaoui then went on to join Medicxi, a biotech venture capital firm.

(Reporting by Steve Holland and Tim Ahmann; Writing by Lisa Lambert; Editing by Chris Reese and David Gregorio)

FIRMEN-BLICK-Mastercard - Not back to the office without a coronavirus vaccine .
May 21 (Reuters) - This is followed by a Reuters look at important developments from the corporate world beyond the top issues of the day: MASTERCARD - Bangalore: The The second largest payment processor in the world offers its employees to return to their office workstations only with the availability of a Covid-19 vaccine. "As soon as there are adequate tests and a vaccine and people feel safe, we will see more employees in the office," said HR manager Michael Fraccaro at Reuters. The U.S.

—   Share news in the SOC. Networks
usr: 1
This is interesting!